Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Accelerating drug approval with better metrics in myeloma

Nicole Gormley • 13 Sep 2019
IMW 2019
General

Nicole Gormley, MD, FDA, Silver Spring, MD, discusses how better metrics can accelerate drug approval in multiple myeloma at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Nicole Gormley

Updated FDA MRD guidelines for hematological malignancies
2:03
Updated FDA MRD guidelines for hematological malignancies
Nicole Gormley • 13 Sep 2019

Related Videos

From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
2:58
From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
Iskra Pusic • 11 Sep 2026
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
3:46
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
Maher Salamoon • 8 Sep 2026
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
2:01
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
Michael Jain • 11 Sep 2026
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
1:46
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
Michael Jain • 11 Sep 2026
The content of VJHemOnc is intended for healthcare professionals